Abeona Therapeutics Inc. (ABEO)
NASDAQ: ABEO · Real-Time Price · USD
5.63
+0.03 (0.54%)
May 13, 2025, 4:00 PM - Market closed
Abeona Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
136
Market Cap
273.25M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
ABEO News
- 1 day ago - Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million - GlobeNewsWire
- 6 days ago - Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 13 days ago - Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease - Benzinga
- 15 days ago - US FDA approves Abeona's skin disorder therapy - Reuters
- 15 days ago - U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) - GlobeNewsWire
- 16 days ago - Undercovered Dozen: 3D Systems, Seritage, Topicus, Timken + - Seeking Alpha
- 22 days ago - Pz-Cel Has Massive Potential For RDEB Patients - Seeking Alpha
- 4 weeks ago - Abeona Therapeutics: A Buy With Major PDUFA Catalyst On April 29 That Should Send Shares Higher - Seeking Alpha